{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T14:19:38Z","timestamp":1778077178721,"version":"3.51.4"},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"13","license":[{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3,27]]},"abstract":"<jats:sec>\n                    <jats:title>Rationale:<\/jats:title>\n                    <jats:p>Zoledronic acid (ZA) is a potent third-generation bisphosphonate widely used to manage bone metastases in prostate cancer. Although effective, ZA is associated with nephrotoxicity, which in rare cases may lead to Fanconi syndrome (FS): a form of acquired proximal renal tubular dysfunction. Clinicians may overlook early signs of FS, especially in patients receiving long-term bisphosphonate therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patient concerns:<\/jats:title>\n                    <jats:p>We report 2 cases of prostate cancer complicated by FS following ZA administration. Patient #1, a 74-year-old male without prior renal dysfunction, developed hypouricaemia 4 months after initiating ZA, and was diagnosed with FS 2 years later. Patient #2, a 66-year-old male with chronic hepatitis B and long-term low-dose adefovir use, exhibited progressive tubular injury shortly after ZA initiation and was diagnosed with FS 4 years later.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Diagnoses:<\/jats:title>\n                    <jats:p>Both patients were diagnosed with acquired FS based on laboratory abnormalities including hypophosphatemia, hypouricaemia, glycosuria, proteinuria, and metabolic acidosis. Differential diagnoses including hereditary FS and other nephrotoxic exposures were excluded.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions:<\/jats:title>\n                    <jats:p>In both patients, ZA was discontinued. Patient #1 was switched to denosumab, and received oral phosphate, potassium, and bicarbonate replacement. Patient #2 also discontinued adefovir and was transitioned to entecavir, alongside targeted supportive therapy with phosphate and vitamin D supplementation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcomes:<\/jats:title>\n                    <jats:p>Renal tubular function improved in both patients following drug withdrawal. Hypouricaemia, glycosuria, electrolyte abnormalities, and acid-base imbalance gradually resolved over 1 to 3 months, supporting a causal relationship between ZA and FS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Lessons:<\/jats:title>\n                    <jats:p>These cases highlight the importance of early recognition and close monitoring of renal tubular function in patients receiving ZA. Screening for FS, including urinalysis, blood gas analysis, and serum electrolytes, should be considered within the first month of therapy and repeated regularly thereafter. Clinicians should maintain high vigilance for FS, especially when ZA is used concurrently with other nephrotoxic agents such as adefovir.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000048113","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T17:01:34Z","timestamp":1774630894000},"page":"e48113","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Fanconi syndrome induced by zoledronic acid: Two case reports"],"prefix":"10.1097","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-7059-793X","authenticated-orcid":false,"given":"Yanrong","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Urology and Office of Academic Research, Affiliated Hospital of Hebei University, Baoding, Hebei Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinhui","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Urology and Office of Academic Research, Affiliated Hospital of Hebei University, Baoding, Hebei Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Office of Academic Research, Affiliated Hospital of Hebei University, Baoding, Hebei Province, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuqi","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Office of Academic Research, Affiliated Hospital of Hebei University, Baoding, Hebei Province, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lili","family":"Qiao","sequence":"additional","affiliation":[{"name":"Department of Urology and Office of Academic Research, Affiliated Hospital of Hebei University, Baoding, Hebei Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2379-9975","authenticated-orcid":false,"given":"Yao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Urology and Office of Academic Research, Affiliated Hospital of Hebei University, Baoding, Hebei Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20260506","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"R2-20260506","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1080\/14656566.2019.1574754","article-title":"Zoledronic acid for the treatment of prostate cancer.","volume":"20","author":"Finianos","year":"2019","journal-title":"Expert Opin Pharmacother"},{"key":"R3-20260506","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1200\/JCO.19.03148","article-title":"Bone health and bone-targeted therapies for prostate cancer: ASCO endorsement of a cancer care ontario guideline.","volume":"38","author":"Saylor","year":"2020","journal-title":"J Clin Oncol"},{"key":"R4-20260506","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1159\/000527931","article-title":"Severe hypophosphatemia as the initial presentation of renal fanconi\u2019s syndrome and distal renal tubular acidosis related to zoledronic acid: a case report and literature review.","volume":"48","author":"Wu","year":"2023","journal-title":"Kidney Blood Press Res"},{"key":"R5-20260506","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1186\/s12885-024-13284-5","article-title":"Evaluate the renal system damage caused by zoledronic acid: a comprehensive analysis of adverse events from FAERS.","volume":"24","author":"Wang","year":"2024","journal-title":"BMC Cancer"},{"key":"R6-20260506","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/qjmed\/hct258","article-title":"Drug-induced renal fanconi syndrome.","volume":"107","author":"Hall","year":"2014","journal-title":"QJM"},{"key":"R7-20260506","doi-asserted-by":"crossref","first-page":"300060520954713","DOI":"10.1177\/0300060520954713","article-title":"Fanconi syndrome induced by adefovir dipivoxil: a case report and clinical review.","volume":"48","author":"Song","year":"2020","journal-title":"J Int Med Res"},{"key":"R8-20260506","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.2147\/DDDT.S192632","article-title":"Low-dose adefovir dipivoxil-induced hypophosphatemia osteomalacia in five chronic hepatitis B virus-infected patients. Is low-dose adefovir dipivoxil-induced nephrotoxicity completely reversible?","volume":"13","author":"Qian","year":"2019","journal-title":"Drug Des Devel Ther"},{"key":"R9-20260506","first-page":"232","article-title":"Transient renal tubular dysfunction following zoledronic acid treatment.","volume":"23","author":"Gnanadeepan","year":"2020","journal-title":"Ann Trop Med Public Health"},{"key":"R10-20260506","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.2169\/internalmedicine.0647-22","article-title":"Fanconi syndrome associated with long-term treatment with zoledronate.","volume":"62","author":"Katsunuma","year":"2023","journal-title":"Intern Med"},{"key":"R11-20260506","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1507\/endocrj.EJ12-0166","article-title":"A case of zoledronate-induced tubulointerstitial nephritis with fanconi syndrome.","volume":"59","author":"Torimoto","year":"2012","journal-title":"Endocr J"},{"key":"R12-20260506","first-page":"5389","article-title":"Acquired hypophosphatemic osteomalacia is easily misdiagnosed or neglected by rheumatologists: a report of 9 cases.","volume":"15","author":"Li","year":"2018","journal-title":"Exp Ther Med"},{"key":"R13-20260506","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1053\/j.ajkd.2021.12.015","article-title":"Zoledronic acid-associated fanconi syndrome in patients with cancer.","volume":"80","author":"Portales-Castillo","year":"2022","journal-title":"Am J Kidney Dis"},{"key":"R14-20260506","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1177\/0960327119829527","article-title":"Characterization of urinary biomarkers and their relevant mechanisms of zoledronate-induced nephrotoxicity using rats and HK-2 cells.","volume":"38","author":"Lan","year":"2019","journal-title":"Hum Exp Toxicol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000048113","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T14:00:46Z","timestamp":1778076046000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000048113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,27]]},"references-count":14,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000048113","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,27]]},"assertion":[{"value":"2025-04-06","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-24","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}